Dr. Cheng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
111 E 210th St
Bronx, NY 10467Phone+1 718-920-4826Fax+1 718-920-8543
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2009 - 2012
UMass Chan Medical SchoolResidency, Internal Medicine, 2006 - 2009
Hunan Medical UniversityClass of 1997
Certifications & Licensure
NY State Medical License 2009 - 2025
Clinical Trials
- Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
- Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Publications & Presentations
PubMed
- Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia/lymphoma.Jianhong An, Erqiang Hu, Yang Shi, Yanan Fang, Naijia Liu
Journal for Immunotherapy of Cancer. 2025-03-25 - Update 2025: Management of Non‑Small-Cell Lung Cancer.Hyein Jeon, Shuai Wang, Junmin Song, Harjot Gill, Haiying Cheng
Lung. 2025-03-25 - Immunotherapy and the Tumor Microenvironment in Brain Metastases from Non-Small Cell Lung Cancer: Challenges and Future Directions.Meng Wang, Jihua Yang, Shuai Wang, Harjot Gill, Haiying Cheng
Current Oncology. 2025-03-16
Press Mentions
Update 2020: Management of Non-Small Cell Lung CancerNovember 11th, 2020- Real World Data Shows Impact of Immunotherapy in Populations Underrepresented in Clinical Trials, According to JNCCN StudyDecember 13th, 2023
- First-Line Immunotherapy Benefits Patients of All Races with NSCLC EquallyDecember 24th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
